Dr. Konstantinos Alexiou

Dr. Konstantinos Alexiou is a medical oncologist and hematologist at AHEPA University Hospital in Thessaloniki, one of Greece's premier academic medical centers and the primary tertiary referral hospital for northern Greece. With 18 years of clinical experience, he has developed expertise in hematologic malignancies and solid tumor oncology.

He completed a hematology and oncology fellowship at the University College London Cancer Institute, one of the UK's leading cancer research centers. This fellowship gave him comprehensive training in lymphoma, leukemia, and novel targeted therapies including monoclonal antibodies and kinase inhibitors.

Dr. Alexiou returned to Thessaloniki where he established the AHEPA Hospital's lymphoma multidisciplinary team and has been a principal investigator in several international clinical trials. Greece's Thessaloniki-based oncology community is notably strong, and AHEPA serves patients from northern Greece, Cyprus, and neighboring Balkan countries.

He is an ESMO member and active in the Hellenic Society of Medical Oncology. He is known for his thorough molecular approach to cancer diagnosis and his integration of the latest targeted therapies into clinical practice.

Dr. Alexiou graduated from the Aristotle University of Thessaloniki School of Medicine in 2003. He completed his internal medicine and hematology/oncology residency at AHEPA University Hospital and undertook a hematology and oncology fellowship at the University College London (UCL) Cancer Institute, London, UK (2008–2010). His PhD from the Aristotle University in 2012 focused on molecular predictors of response in diffuse large B-cell lymphoma. He is an ESMO member and is certified by the Hellenic Medical Association in oncology and hematology.

Dr. Alexiou's primary clinical expertise is in hematologic malignancies including Hodgkin and non-Hodgkin lymphoma, chronic and acute leukemias, and multiple myeloma. He designs and administers chemotherapy regimens (R-CHOP, ABVD, BEP, and others), targeted therapy (ibrutinib, venetoclax, rituximab, daratumumab), and CAR-T cell therapy coordination. He also manages solid tumor oncology including breast, lung, and colorectal cancer. He performs bone marrow biopsies and intrathecal chemotherapy and coordinates stem cell transplant referrals.

Dr. Alexiou has published over 35 peer-reviewed articles in journals including Haematologica, the European Journal of Haematology, and the Annals of Oncology. His research focuses on lymphoma molecular subtypes, novel targeted therapies in hematologic malignancies, and clinical trial outcomes in Greek and Balkan patient populations. He collaborates with oncology groups at UCL and presents at ESMO and ASH (American Society of Hematology) congresses.

Dr. Alexiou speaks Greek and English and has experience treating international patients from Cyprus, the Balkans, and the broader Greek diaspora. AHEPA University Hospital coordinates international patient care. Video consultations are available for second opinions on hematologic malignancies. Thessaloniki is accessible by direct flights from many European cities and serves as a medical hub for the northern Balkans.

Dr. Alexiou received the Hellenic Society of Medical Oncology (HESMO) Award for Research Excellence in 2015. He was recognized by AHEPA University Hospital for establishing the lymphoma multidisciplinary team. He received ESMO recognition for his clinical trial contributions and was selected as a presenter at the ASH Annual Meeting in 2019.